VMP001 Plasmodium vivax malaria vaccine antigens

Type
Compound(s)

WRAIR has developed and patented a novel hybrid molecule containing both Type 1 VK210 and Type 2 VK247 P. vivax repeats. This molecule VMP001 induces a potent immune response to both Type 1 and Type 2 sporozoites in animal models. In addition to the repeat region, the recombinant molecule contains the N- and C-terminal regions of CS protein including several T and B cell epitopes.

Disease
Malaria
Research areas
Vaccine
Condition of use

In house only